Marilyn Mulay

830 total citations
17 papers, 644 citations indexed

About

Marilyn Mulay is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Marilyn Mulay has authored 17 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Marilyn Mulay's work include Cancer, Hypoxia, and Metabolism (6 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer Treatment and Pharmacology (4 papers). Marilyn Mulay is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer Treatment and Pharmacology (4 papers). Marilyn Mulay collaborates with scholars based in United States, India and Singapore. Marilyn Mulay's co-authors include Lee S. Rosen, Melissa Dinolfo, Chisato Tomoda, Masahiro Sugawara, Elaine K. Wong, Jerome M. Hershman, Razelle Kurzrock, Roy S. Herbst, Michelle Purdom and Michael Bass and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Oncotarget.

In The Last Decade

Marilyn Mulay

17 papers receiving 630 citations

Peers

Marilyn Mulay

ONCOL

PRM

EDM

John Frye United States

Jinhyun Cho South Korea

Sven Gogov Switzerland

Thierry Nguyen France

Mona Fouad Egypt

R. Basser Australia

Luciano Canobbio Italy

Sally Baron‐Hay Australia

В. С. Медведев Russia

Daria Arbogast United States

John Frye United States

Marilyn Mulay

286 ×0.8

ONCOL

172 ×0.7

PRM

222 ×0.9

230 ×1.7

EDM

91 ×0.9

Citations per year, relative to Marilyn Mulay Marilyn Mulay (= 1×) peers John Frye

Countries citing papers authored by Marilyn Mulay

Since Specialization

Citations

This map shows the geographic impact of Marilyn Mulay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marilyn Mulay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marilyn Mulay more than expected).

Fields of papers citing papers by Marilyn Mulay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marilyn Mulay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marilyn Mulay. The network helps show where Marilyn Mulay may publish in the future.

Co-authorship network of co-authors of Marilyn Mulay

This figure shows the co-authorship network connecting the top 25 collaborators of Marilyn Mulay. A scholar is included among the top collaborators of Marilyn Mulay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marilyn Mulay. Marilyn Mulay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Iyer, Ramya, Marilyn Mulay, Shyam Pyari Jaiswar, et al.. (2025). Implementation of circulating tumor DNA (ctDNA) testing in precision oncology: A four-year experience from a tertiary cancer center in India. PubMed. 9. 100319–100319. 1 indexed citations

Hong, David S., Razelle Kurzrock, Marilyn Mulay, et al.. (2014). A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 5(22). 11154–11167. 12 indexed citations

Rosen, Lee S., Igor Puzanov, Gregory Friberg, et al.. (2012). Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(12). 3414–3427. 30 indexed citations

Chuah, Benjamin, Boon Cher Goh, Richie Soong, et al.. (2010). Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients. Cancer Science. 102(2). 478–483. 105 indexed citations

Robert, Francisco, Michael Gordon, Lee S. Rosen, et al.. (2010). Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.. Journal of Clinical Oncology. 28(15_suppl). 3038–3038. 6 indexed citations

Bello, Carlo L., Marilyn Mulay, Xin Huang, et al.. (2009). Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib. Clinical Cancer Research. 15(22). 7045–7052. 74 indexed citations

Limentani, Steven, et al.. (2008). A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results. Journal of Clinical Oncology. 26(15_suppl). 3556–3556. 16 indexed citations

Sarantopoulos, John, Akira Mita, Marilyn Mulay, et al.. (2008). A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). Journal of Clinical Oncology. 26(15_suppl). 3583–3583. 26 indexed citations

Patnaik, Amita, Lee S. Rosen, Lauren V. Wood, et al.. (2008). A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results. Journal of Clinical Oncology. 26(15_suppl). 3558–3558. 12 indexed citations

10.

Borad, Mitesh J., Lee S. Rosen, Gayle Jameson, et al.. (2008). Phase I dose finding and pharmacokinetic study of NKTR-102 (PEGylated irinotecan): Early evidence of anti-tumor activity. Journal of Clinical Oncology. 26(15_suppl). 13518–13518. 1 indexed citations

11.

Rosen, Lee S., Razelle Kurzrock, Marilyn Mulay, et al.. (2007). Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 25(17). 2369–2376. 152 indexed citations

12.

Wong, Elaine K., Lee S. Rosen, Marilyn Mulay, et al.. (2007). Sunitinib Induces Hypothyroidism in Advanced Cancer Patients and May Inhibit Thyroid Peroxidase Activity. Thyroid. 17(4). 351–355. 159 indexed citations

13.

Bello, Carlo L., Marilyn Mulay, Melissa Dinolfo, et al.. (2007). 709 POSTER Characterization of electrocardiographic QTc interval in patients (pts) with advanced solid tumors: pharmacokinetic–pharmacodynamic evaluation of sunitinib. European Journal of Cancer Supplements. 5(4). 110–110. 4 indexed citations

14.

Mulay, Marilyn, et al.. (2006). Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 13061–13061. 12 indexed citations

15.

Mulay, Marilyn, Casey Cunningham, John Nemunaitis, et al.. (2006). 651 POSTER A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors. European Journal of Cancer Supplements. 4(12). 196–196. 6 indexed citations

16.

Rosen, Lee S., Razelle Kurzrock, Edward F. Jackson, et al.. (2005). Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3013–3013. 25 indexed citations

17.

Mulay, Marilyn. (2002). Making the decision : a cancer patient's guide to clinical trials. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact